QCM
MDGL icon

Qsemble Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Qsemble Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,513
Closed -$458K – 545
2025
Q2 		$458K Buy
+1,513
New +$451K 0.04% 330

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Qsemble Capital Management's MDGL Position: Q3 2025 in Review

Qsemble Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 1,513 shares — an estimated $458K sold.

Qsemble Capital Management first reported a position in MDGL in Q2 2025 and held it in 1 quarter. The position peaked at $458K in Q2 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Qsemble Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Qsemble Capital Management sold 1,513 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $458K.
  • Qsemble Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Qsemble Capital Management's Madrigal Pharmaceuticals position peaked at $458K in Q2 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Qsemble Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.